{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:56:31Z","timestamp":1769630191367,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but potentially serious, adverse event that can occur after exposure to bone-modifying agents (BMAs; e.g., bisphosphonates, denosumab, and antiangiogenic therapies). BMAs are typically used at higher doses to prevent skeletal-related events in cancer patients and at lower doses for osteoporosis\/bone loss. MRONJ can cause significant pain, reduce quality of life, and can be difficult to treat, requiring a multiprofessional approach to care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We reviewed the literature and guidelines to summarize a practical guide on MRONJ for nurses and other allied healthcare professionals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>While there is a risk of MRONJ with BMAs, this should be considered in relation to the benefits of treatment. Nurses and other allied healthcare professionals can play a key role alongside physicians and dentists in assessing MRONJ risk, identifying MRONJ, counseling the patient on the benefit\u2013risk of BMA treatment, preventing MRONJ, and managing the care pathway of these patients. Assessing patients for MRONJ risk factors before starting BMA treatment can guide preventative measures to reduce the risk of MRONJ. Nurses can play a pivotal role in facilitating multiprofessional management of MRONJ by communicating with patients to ensure compliance with preventative measures, and with patients\u2019 physicians and dentists to ensure early detection and referral for prompt treatment of MRONJ.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This review summarizes current evidence on MRONJ and provides practical guidance for nurses, from before BMA treatment is started through to approaches that can be taken to prevent and manage MRONJ in patients receiving BMAs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00520-020-05440-x","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:02:32Z","timestamp":1587315752000},"page":"4019-4029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals"],"prefix":"10.1007","volume":"28","author":[{"given":"Lawrence","family":"Drudge-Coates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Schi\u00f8dt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A. M.","family":"van Muilekom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Demonty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"5440_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"5440_CR2","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"5440_CR3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27:383\u2013394","journal-title":"Support Care Cancer"},{"key":"5440_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 127:117\u2013135","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"Suppl 3","key":"5440_CR5","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 25(Suppl 3):iii124\u2013iii137","journal-title":"Ann Oncol"},{"key":"5440_CR6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA (2018) Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 36:812\u2013818","journal-title":"J Clin Oncol"},{"key":"5440_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"5440_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, CA MC, Staffa JA, Willy M, Selby JV, Go AS, Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure Investigators (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243\u2013253","journal-title":"J Oral Maxillofac Surg"},{"key":"5440_CR9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","volume":"27","author":"A Khan","year":"2016","unstructured":"Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 27:853\u2013859","journal-title":"Osteoporos Int"},{"key":"5440_CR10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","volume":"16","author":"J Chang","year":"2018","unstructured":"Chang J, Hakam AE, McCauley LK (2018) Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep 16:584\u2013595","journal-title":"Curr Osteoporos Rep"},{"key":"5440_CR11","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","volume":"68","author":"S Otto","year":"2010","unstructured":"Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837\u20132845","journal-title":"J Oral Maxillofac Surg"},{"key":"5440_CR12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcms.2017.01.006","volume":"45","author":"S Panya","year":"2017","unstructured":"Panya S, Fliefel R, Probst F, Troltzsch M, Ehrenfeld M, Schubert S, Otto S (2017) Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 45:357\u2013363","journal-title":"J Craniomaxillofac Surg"},{"key":"5440_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M (2018) Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 69:177\u2013187","journal-title":"Cancer Treat Rev"},{"key":"5440_CR14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"5440_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","volume":"53","author":"S Fedele","year":"2015","unstructured":"Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, Fusco V, Gabriele M, Ottolenghi L, Valsecchi S, Porter S, Fung PP, Saia G, Campisi G, Bedogni A (2015) Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 53:13\u201317","journal-title":"Br J Oral Maxillofac Surg"},{"key":"5440_CR16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","volume":"117","author":"M Schiodt","year":"2014","unstructured":"Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204\u2013213","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"7","key":"5440_CR17","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/odi.13160","volume":"25","author":"M Schiodt","year":"2019","unstructured":"Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, Herlofson BB, Ristow O, Kofod T (2019) Workshop of European task force on medication-related osteonecrosis of the jaw-current challenges. Oral Dis 25(7):1815\u20131821","journal-title":"Oral Dis"},{"key":"5440_CR18","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3390\/dj5010013","volume":"5","author":"M Migliario","year":"2017","unstructured":"Migliario M, Mergoni G, Vescovi P, Martino I, Alessio M, Benzi L, Reno F, Fusco V (2017) Osteonecrosis of the jaw (ONJ) in osteoporosis patients: report of delayed diagnosis of a multisite case and commentary about risks coming from a restricted ONJ definition. Dent J 5:E13","journal-title":"Dent J"},{"key":"5440_CR19","first-page":"53","volume":"4","author":"G Ficarra","year":"2007","unstructured":"Ficarra G, Beninati F (2007) Bisphosphonate \u2013 related osteonecrosis of the jaws: the point of view of the oral pathologist. Clin Cases Miner Bone Metab 4:53\u201357","journal-title":"Clin Cases Miner Bone Metab"},{"key":"5440_CR20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"5440_CR21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7257\/1053-816X.2016.36.3.117","volume":"36","author":"B Turner","year":"2016","unstructured":"Turner B, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P (2016) Retrospective audit: does prior assessment by oral and maxillofacial surgeons reduce the risk of osteonecrosis of the jaw in patients receiving bone-targeted therapies for metastatic cancers to the skeleton? Part II. Urol Nurs 36:117\u2013133","journal-title":"Urol Nurs"},{"key":"5440_CR22","doi-asserted-by":"crossref","unstructured":"Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL, Fisch MJ, Henry NL, Hershman DL, Gralow J (2019) Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211. American Society of Clinical Oncology (ASCO) 2019 Annual Meeting","DOI":"10.1200\/JCO.2019.37.15_suppl.11502"},{"key":"5440_CR23","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3:906\u2013912","journal-title":"JAMA Oncol"},{"key":"5440_CR24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663\u2013670","journal-title":"Lancet Oncol"},{"key":"5440_CR25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447\u2013455","journal-title":"Support Care Cancer"},{"key":"5440_CR26","unstructured":"Amgen Europe BV (2020) Xgeva (denosumab) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf. Accessed 27 Feb 2020"},{"key":"5440_CR27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1159\/000343950","volume":"35","author":"C Then","year":"2012","unstructured":"Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, Baumann P, Schmidmaier R, Bumeder I, Oduncu FS (2012) Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 35:658\u2013664","journal-title":"Onkologie"},{"key":"5440_CR28","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","volume":"104","author":"NB Watts","year":"2019","unstructured":"Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, Tierney A, Wagman RB, McClung M (2019) Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab 104:2443\u20132452","journal-title":"J Clin Endocrinol Metab"},{"key":"5440_CR29","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","volume":"45","author":"S Aljohani","year":"2017","unstructured":"Aljohani S, Fliefel R, Ihbe J, Kuhnisch J, Ehrenfeld M, Otto S (2017) What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Craniomaxillofac Surg 45:1493\u20131502","journal-title":"J Craniomaxillofac Surg"},{"key":"5440_CR30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43:847\u2013854","journal-title":"J Craniomaxillofac Surg"},{"key":"5440_CR31","unstructured":"Fleisher KE, Kontio R, Otto S (2016) Antiresorptive drug-related osteonecrosis of the jaw (ARONJ) \u2013 a guide to research. AO Foundation, Switzerland: Davos Platz"},{"key":"5440_CR32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11914-011-0056-1","volume":"9","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep 9:141\u2013148","journal-title":"Curr Osteoporos Rep"},{"key":"5440_CR33","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1210\/jc.2019-00271","volume":"104","author":"S Ferrari","year":"2019","unstructured":"Ferrari S, Butler PW, Kendler DL, Miller PD, Roux C, Wang AT, Huang S, Wagman RB, Lewiecki EM (2019) Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment. J Clin Endocrinol Metab 104:3450\u20133461","journal-title":"J Clin Endocrinol Metab"},{"key":"5440_CR34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12911-019-0862-4","volume":"19","author":"A Ankolekar","year":"2019","unstructured":"Ankolekar A, Vanneste BGL, Bloemen-van Gurp E, van Roermund JG, van Limbergen EJ, van de Beek K, Marcelissen T, Zambon V, Oelke M, Dekker A, Roumen C, Lambin P, Berlanga A, Fijten R (2019) Development and validation of a patient decision aid for prostate cancer therapy: from paternalistic towards participative shared decision making. BMC Med Inform Decis Mak 19:130","journal-title":"BMC Med Inform Decis Mak"},{"key":"5440_CR35","unstructured":"Scottish Dental Clinical Effectiveness Programme (2017) Oral health management of patients at risk of medication-related osteonecrosis of the jaw: dental clinical guidance http:\/\/www.sdcep.org.uk\/wp-content\/uploads\/2017\/04\/SDCEP-Oral-Health-Management-of-Patients-at-Risk-of-MRONJ-Guidance-full.pdf. Accessed 14 Apr 2020"},{"key":"5440_CR36","unstructured":"The Royal College of Obstetricians and Gynaecologists (2015) Understanding how risk is discussed in healthcare. https:\/\/www.rcog.org.uk\/globalassets\/documents\/patients\/patient-information-leaflets\/pi-understanding-risk.pdf. Accessed 14 Apr 2020"},{"key":"5440_CR37","unstructured":"European Oral Care in Cancer Group (2017) Oral care guidance and support 2017. http:\/\/www.eocc.co.uk\/wp-content\/uploads\/2018\/09\/EOCC-English-Guidance.pdf. Accessed 14 Apr 2020"},{"key":"5440_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0036-1592367","volume":"20","author":"T M\u00fccke","year":"2016","unstructured":"M\u00fccke T, Krestan CR, Mitchell DA, Kirschke JS, Wutzl A (2016) Bisphosphonate and medication-related osteonecrosis of the jaw: a review. Semin Musculoskelet Radiol 20:305\u2013314","journal-title":"Semin Musculoskelet Radiol"},{"key":"5440_CR39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","volume":"125","author":"AA Owosho","year":"2018","unstructured":"Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, Estilo CL (2018) Medication-related osteonecrosis of the jaw: an update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 125:440\u2013445","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"5440_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2018.08.003","volume":"85","author":"H Karna","year":"2018","unstructured":"Karna H, Gonzalez J, Radia HS, Sedghizadeh PP, Enciso R (2018) Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: a systematic review with meta-analyses. Oral Oncol 85:15\u201323","journal-title":"Oral Oncol"},{"key":"5440_CR41","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.oooo.2012.08.442","volume":"117","author":"MJ Heufelder","year":"2014","unstructured":"Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F (2014) Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 117:e429\u2013e435","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"5440_CR42","doi-asserted-by":"crossref","first-page":"e024376","DOI":"10.1136\/bmjopen-2018-024376","volume":"9","author":"A Sturrock","year":"2019","unstructured":"Sturrock A, Preshaw PM, Hayes C, Wilkes S (2019) Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open 9:e024376","journal-title":"BMJ Open"},{"key":"5440_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.bdj.2017.1039","volume":"224","author":"V Patel","year":"2018","unstructured":"Patel V, Mansi J, Ghosh S, Kwok J, Burke M, Reilly D, Nizarali N, Sproat C, Chia K (2018) MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 224:74\u201379","journal-title":"Br Dent J"},{"key":"5440_CR44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdn630","volume":"20","author":"T Van den Wyngaert","year":"2009","unstructured":"Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331\u2013336","journal-title":"Ann Oncol"},{"key":"5440_CR45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jcms.2016.05.018","volume":"44","author":"S Otto","year":"2016","unstructured":"Otto S, Ristow O, Pache C, Troeltzsch M, Fliefel R, Ehrenfeld M, Pautke C (2016) Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: a prospective cohort study. J Craniomaxillofac Surg 44:1073\u20131080","journal-title":"J Craniomaxillofac Surg"},{"key":"5440_CR46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tripleo.2011.02.037","volume":"112","author":"O Nicolatou-Galitis","year":"2011","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA (2011) Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:195\u2013202","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"5440_CR47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","volume":"43","author":"O Ristow","year":"2015","unstructured":"Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C (2015) Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 43:290\u2013293","journal-title":"J Craniomaxillofac Surg"},{"key":"5440_CR48","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","volume":"26","author":"M Schiodt","year":"2018","unstructured":"Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, Fedele S, Jandial D, Zhang J, Ma H, Saunders DP (2018) A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26:1905\u20131915","journal-title":"Support Care Cancer"},{"key":"5440_CR49","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1002\/hed.25944","volume":"41","author":"TE de Souza","year":"2019","unstructured":"de Souza TE, de Castro TF, Michellon FC, Passoni ACC, Ortega LJA, Iwaki LCV, da Silva MC (2019) Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: systematic review. Head Neck 41:4209\u20134228","journal-title":"Head Neck"},{"key":"5440_CR50","first-page":"CD008455","volume":"2","author":"V Rollason","year":"2016","unstructured":"Rollason V, Laverriere A, MacDonald LC, Walsh T, Tramer MR, Vogt-Ferrier NB (2016) Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev 2:CD008455","journal-title":"Cochrane Database Syst Rev"},{"key":"5440_CR51","first-page":"CD012432","volume":"10","author":"NH Beth-Tasdogan","year":"2017","unstructured":"Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O (2017) Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev 10:CD012432","journal-title":"Cochrane Database Syst Rev"},{"key":"5440_CR52","first-page":"2684924","volume":"2018","author":"O Di Fede","year":"2018","unstructured":"Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, Sipmo Onj B, Campisi G (2018) The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018:2684924","journal-title":"Biomed Res Int"},{"key":"5440_CR53","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1185\/03007995.2016.1170005","volume":"32","author":"A Taguchi","year":"2016","unstructured":"Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S, Japan Osteoporosis S (2016) Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin 32:1261\u20131268","journal-title":"Curr Med Res Opin"},{"key":"5440_CR54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","volume":"22","author":"L Ramaglia","year":"2018","unstructured":"Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A (2018) Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig 22:597\u2013615","journal-title":"Clin Oral Investig"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05440-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:13:52Z","timestamp":1618787632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05440-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5440"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05440-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LD-C has acted as a consultant for Amgen.GD is employed by Amgen and holds stocks in Amgen.HAMvM has participated in advisory boards for Janssen and Amgen, and received a travel grant from Astellas.SO has received honoraria from Amgen.TVdW has received research funding and speaker fees from Amgen.MS has acted as a consultant for Amgen, and received research funding from Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript does not include any patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}